After a pause in deal activity because of the COVID-19 pandemic at the start of 2020, M&A in the life sciences and health care sector rebounded during the second half of the year. Deal activity trended toward a greater volume of smaller bolt-on acquisitions and partnering deals in lieu of the mega deals executed in preceding years.
Financing for life sciences and health care companies was strong across the board, from venture capital to IPOs and follow-on offerings. In addition, many of the drivers for transacting – access to new products and technologies, rationalizing and filling revenue gaps across products lines, and venture or PE-backed companies looking for an exit – remained in play.
Hogan Lovells activities
Our global Life Sciences and Health Care industry sector continues to regularly release guidance, webinars, and podcasts addressing the pandemic’s impact on the sector, which we catalog in our COVID-19 Resource Guide.
We released our annual Hogan Lovells LS&HC Horizons publication, providing high-level insights into opportunities and challenges in the sector, along with our Talking the Cure podcast series, which seeks to foresee the industry issues facing our clients. Our Global Digital Health Team launched Virtual Health Horizons to explore the opportunities and potential legalhurdles in telehealth and remote monitoring.